Product logins

Find logins to all Clarivate products below.


Biosimilars | Market Events and Forecast | Respiratory | 2025

In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Biosimilars – Corporate Strategies – Biosimilar Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biosimilars – Corporate Strategies – Reference Brand Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Current Treatment: Physician Insights – Chronic Obstructive Pulmonary Disease (EU5)
The treatment landscape for chronic obstructive pulmonary disease (COPD) has significantly evolved in the past few years. A plethora of COPD treatments are available in the EU5. These include long-…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 853 currently available and novel biosimilar products, detailing…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Ventolin HFA) and maintenance therapy to prevent…